Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06438179 versus EU infliximab with methotrexate in rheumatoid arthritis
2013-004148-49Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in rheumatoid arthritis (RA) (2 arms), sponsored by Pfizer. Primary endpoint: ACR20 response at Week 14. Started May 2014; status: completed.
02
Drugs
infliximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-004148-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004148-49.